Day: July 1, 2025

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”) announces that it will apply to the TSX Venture Exchange (the “Exchange”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein. Convertible Debenture Amendments The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “Convertible Debentures”) issued pursuant to the Company’s non-brokered private placement of Convertible Debenture units closed on May 29, 2023 (the “Debenture Unit Private Placement”). The Convertible Debentures are governed by an indenture dated May 29, 2023 (the “Indenture”) between the Company...

WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 3,636,363 shares of its common stock at the...

CALGARY, Alberta, June 30, 2025 (GLOBE NEWSWIRE) — Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of cutting-edge radio frequency (“RF”) power-to-heat technologies targeting process heat for critical minerals, amine regeneration (for carbon capture and other applications), and enhanced oil production, is pleased to announce a non-brokered private placement of units of the Company (the “Units”), at a price of $0.10 per Unit (the “Unit Price”), for gross proceeds of up to $1,500,000 (the “Private Placement”). Details of the Private Placement Pursuant to the Private Placement, each Unit will consist of (i) one (1) common share in the capital of the Company (a “Common Share”); and (ii) one (1) Common Share purchase warrant of the Company (a “Warrant”). Each Warrant will entitle the holder thereof...

SANTA MONICA, CA, June 30, 2025 (GLOBE NEWSWIRE) — Oliveda International, Inc. (OTC Pink: OLVI) today announced that after a true waterless beauty movement emerged in the United States within just two years, with over 60,000 waterless beauty consultants, and Olive Tree People USA Inc. exploded from 40 to over 10,000 packages per day and up to 4 million in sales per day in 2024 alone, olive farmer and CEO Thomas Lommel has set the course for global expansion by establishing subsidiaries in Canada and Europe. Olive Tree People Canada Inc., based in Edmonton, Alberta, will begin its pre-launch phase in Canada in July 2025, and in October 2025, Olive Tree People Europe AG, based in Switzerland, will drive expansion in Europe. As the Los Angeles Times reported in May 2025, Olive Tree People Inc. is the fastest-growing waterless beauty...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) — Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation. In follow-up to the successful Type B meeting in early 2024 under the existing Regenerative Medicine Advanced Therapy (RMAT) designation for REVASCOR in end-stage HFrEF patients with a left ventricular assist device (LVAD), where FDA stated that the results of the presented studies could support accelerated approval, Mesoblast met with FDA on June 3, 2025 to align on key items for BLA filing....

Toronto, Ontario and Nucla, Colorado, June 30, 2025 (GLOBE NEWSWIRE) —  Western Uranium & Vanadium Corp. (CSE: WUC) (OTCQX: WSTRF) (“Western” or the ”Company”) is pleased to announce the results of the Company’s Annual General and Special Meeting of shareholders (the “Meeting”) held in Nucla, Colorado on June 27, 2025. Proxy votes were cast for common shares representing approximately 51% of the issued and outstanding common shares of the Company as at the record date for the Meeting. Each of the other matters put forward before shareholders for consideration and approval at the Meeting, as described in the Company’s management information circular dated May 22, 2025, was duly approved by the requisite number of votes. Re-Election of DirectorsAt the Meeting, the shareholders re-elected all of the directors proposed by...

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) — Swiss Water Decaffeinated Coffee Inc. (TSX:SWP) (“Swiss Water” or the “Company”) is pleased to announce it has entered into an agreement with Mill Road Capital II, L.P. (“Mill Road”) to purchase from Mill Road the outstanding share purchase warrant entitling Mill Road to acquire up to 2,250,000 common shares of Swiss Water. The share purchase warrant has an exercise price of $3.33 per share and expires on April 30, 2026. The purchase price for the share purchase warrant is $675,000. Completion of the purchase is anticipated to be July 3, 2025. “The cancellation of the Warrants removes an overhang on the share price trading and will permit the shares to trade without this influence going forward. We believe that shareholders will also benefit from the clarity being provided...